Cancer research includes investigation of interactions between cancer cells and the immune system, helping researchers better understand how the body’s natural defenses respond to cancer. In this context, the developing field of immuno-oncology investigates how the body’s natural defenses can be used or modified to recognize and target cancer cells. and respond to cancer cells.
In contrast to conventional anticancer agents like chemotherapy, radiation and hormone therapy that primarily act directly on cancer cells, immuno-oncology approaches are designed to interact with different components of the immune system, e.g. immune checkpoint inhibitors, cancer treatments by means of genetically modified cells, therapeutic cancer vaccines, etc.
Cancer research by pharmaceutical companies, biotechnology organizations, universities, and best oncology companies focused on cancer innovation is being conducted in laboratories around the world to investigate various approaches, including immune checkpoint inhibitors, cancer vaccines, and other immune-based therapies, both as single agents and in combination with conventional treatments.
Understanding the Science Behind Immuno-Oncology
An individual’s immune system is made up of several cells, proteins and signaling pathways that act to defend against foreign substances such as bacteria, viruses and others that can cause disease. Additionally, abnormal cells that could develop into cancer can sometimes be recognized and destroyed by the immune system.
Some cancer cells can develop ways to hide from the immune system and/or prevent it from functioning properly. For example, some cancer cells can express proteins that inhibit the function of T-cells. In addition, some cancer cells can modify the surrounding tissue in such a way that it hampers the immune response. Research into the ways tumors evade immune recognition and how their immune evasion mechanisms can be addressed are focal points of research in immuno-oncology.
According to the National Cancer Institute (NCI), immunotherapy refers to a variety of approaches that have been explored to help the immune system kill cancer cells. Some of these approaches include immune checkpoint inhibitors, T-cell transfer therapies, monoclonal antibodies against tumors or their surroundings, therapeutic cancer vaccines and other substances that can affect the immune system.
Four Major Approaches Being Investigated
Immuno-oncology comprises several different therapeutic approaches, each based on different biological principles.
Immune Checkpoint Inhibitors
Tumor cells sometimes interfere with T-cell activity through immune checkpoint proteins and related signaling pathways that normally regulate immune responses. Clinical studies have evaluated immune checkpoint inhibitors that target these signaling pathways to help support T-cell activity, which may enhance the immune system’s ability to recognize and respond to cancer cells.
Some of these drugs are already approved for certain types of cancer and are being studied in other types of cancer as well. Use of these drugs depends on the type of cancer, the stage and other characteristics of the cancer, and the presence of certain biomarkers.
CAR-T Cell Therapy
Chimeric Antigen Receptor T-cell (CAR-T) Therapy: This form of cellular immunotherapy utilizes a patient’s own T-cells, typically collected from the blood, which are then modified outside of the body to include a chimeric antigen receptor (CAR). This CAR is engineered to recognize a specific antigen expressed by the patient’s cancer cells. The modified cells are then returned to the patient with the intent of recognizing cancer cells that express the target antigen.
While there are many studies for the use of CAR-T cells in blood cancers, additional approaches are being explored for use in solid tumors. Challenges in this type of therapy include the tumor microenvironment, the choice of tumor antigen and the cancer’s ability to suppress immune responses.
Therapeutic Cancer Vaccines
Cancer vaccines: Here, we distinguish between vaccines to prevent cancer by protecting against cancer-associated infections and vaccines to treat existing cancer by stimulating an antitumor immune response. Approaches using tumor antigens and tumor-specific neoantigens from individual patients are under investigation by researchers working with therapeutic cancer vaccines.
Tumor-Infiltrating Lymphocyte Therapy
Tumor-infiltrating lymphocytes (TILs) are immune cells within a tumor or within the surrounding tissue of a tumor. In TIL therapy, the TILs are removed from a patient’s tumor, grown in the laboratory and then given back to the patient as part of their cancer treatment. The use of TILs for cancer treatment is under investigation to better understand how naturally occurring tumor-reactive cells can be used in cancer treatment.
Why Biomarkers Matter in Immuno-Oncology
Testing for specific biomarkers is an important tool in research into immuno-oncology as well as in the clinical treatment of individual patients. Biomarkers can supply information about the molecular and biological characteristics of cancer.
Examples include PD-L1 expression on cancer cells and other tumor characteristics, such as microsatellite instability or mismatch repair deficiency, which can help identify patients who may be eligible for certain immunotherapy approaches. Additionally, the amount of tumor mutations (tumor mutational burden or TMB), as well as other features, are being studied to better understand the interaction of these characteristics with an antitumor immune response.
Biomarker testing can identify a variety of genetic and protein changes in cancer, which can help guide treatment decisions. However, the presence of a biomarker does not necessarily mean that patients will experience clinical benefit from a particular immunotherapy.
Challenges in Developing Immuno-Oncology Therapies
Much remains to be learned in immuno-oncology. One challenge involves tumors that become resistant to treatment, either because the tumor does not respond to treatment from the outset or because the tumor initially responds but subsequently progresses.
The tumor microenvironment can also be studied in greater detail. The interaction between a tumor and its surrounding environment, including non-cancerous cells, the extracellular matrix, blood vessels and other supporting cells, creates a complex biological environment that can interfere with immune responses.
Side effects, including serious adverse effects, can be caused by the inflammatory effects of a treatment designed to stimulate an immune system response. Side effects vary depending on the treatment as well as from patient to patient. There is considerable interest in exploring additional treatment strategies, including alternative immunotherapeutic approaches and combination regimens, as well as further understanding the role of biomarkers.
The Role of Research Partnerships and Biopharmaceutical Development
Development of investigational immuno-oncology therapies involves multidisciplinary collaboration among pharmaceutical developers, biotechnology researchers, hospitals, academic institutions and contract research organizations (CROs) worldwide.
Pharmaceutical companies, biotechnology organizations, academic research institutions, and oncology research organizations continue to contribute to ongoing immuno-oncology research. However, investigational approaches must undergo clinical evaluation and receive approval from relevant regulatory bodies before they can be used for the treatment of cancer in specific settings. Regulatory bodies evaluate investigational therapies by requiring clinical evidence of safety and efficacy for the treatment of patients with cancer. The US Food and Drug Administration (FDA) Oncology Center of Excellence conducts scientific and regulatory work in immuno-oncology, including activities related to clinical trial approaches and the development of new immune-based therapeutic agents.
What Lies Ahead for Immuno-Oncology?
Future research around immuno-oncology will involve cancer vaccines, such as those developed on an individual basis for a particular patient, as well as engineered cells that can be used to target tumors. In addition, there is ongoing investigation into the various immune checkpoint pathways that can be targeted to influence tumor growth. Many of these approaches are also being investigated in combination.
There is increasing interest in using the growing amount of genomic information to better understand tumors, identify potential new cancer drug targets and determine how different tumors may respond to treatments. Best oncology companies active in oncology research, biotechnology organizations, and academic institutions continue to contribute to immuno-oncology research and development.
Investigational approaches must undergo clinical studies to establish their safety and efficacy in treating patients with cancer. While there has been progress in understanding immune resistance to treatment and the biological characteristics of different types of cancers, further research is needed.
Image by Tara Winstead from Pexels
Disclaimer: This article is intended to provide a general overview of developments in oncology research and development. It is not intended to promote or recommend any specific treatment, product, or company.
The editorial staff of Medical News Bulletin had no role in the preparation of this post. The views and opinions expressed in this post are those of the advertiser and do not reflect those of Medical News Bulletin. Medical News Bulletin does not accept liability for any loss or damages caused by the use of any products or services, nor do we endorse any products, services, or links in Sponsored Articles.